Skip to main content
    C

    Crispr Therapeutics AG (CRSP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $40.37
    -1.87 (-4.43%)

    Market Cap: $4.10B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Crispr Therapeutics AG (CRSP) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Crispr Therapeutics AG (CRSP) trades at 155.2x sales and 2.4x book value. Its P/S of 155.2x is above its 5-year median of 35.5x. Its forward P/E is 23.4x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E23.4x
    Price to sales155.2x
    Price to book2.4x
    PEGN/A
    FCF yield-9.6%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 264.3% above 42.6x and its P/B is 22.6% below 3.1x.

    MultipleCurrent5-year median10-year median
    P/S155.2x35.5x42.6x
    P/B2.4x2.4x3.1x
    Medians of month-end values through Oct 2026: 51 to 60 months (5-year) and 102 to 119 months (10-year).

    Valuation History

    Over the 7 of the 10 year ends shown that have a P/S, its P/S ranged from 6.3x in 2021 to 426.9x in 2018.

    Year endPriceP/EP/SP/B
    2025$52.44N/AN/A2.5x
    2024$39.36N/A90.1x1.7x
    2023$62.60N/A13.5x2.7x
    2022$40.65N/AN/A1.7x
    2021$75.7817.1x6.3x2.4x
    2020$153.11N/AN/A6.5x
    2019$60.9162.8x11.8x3.9x
    2018$28.57N/A426.9x3.8x
    2017$23.48N/A25.5x5.7x
    2016$20.26N/A52.2x3.5x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    Frequently Asked Questions About CRSP

    What is CRSP's forward P/E ratio?

    Crispr Therapeutics AG has a forward P/E ratio of 23.4x.

    What is CRSP's price to sales ratio?

    Crispr Therapeutics AG has a price to sales ratio of 155.2x.